Browsing Tag
RESTORE
3 posts
Can Nanoscope make severe retinitis pigmentosa treatable without knowing the mutation?
The FDA has accepted Nanoscope Therapeutics’ BLA for MOGENRY, a one-time optogenetic therapy designed to restore useful vision in severe retinitis pigmentosa regardless of the patient’s underlying mutation.
Nanoscope moves mutation-agnostic MOGENRY gene therapy into FDA review
The FDA has accepted Nanoscope Therapeutics’ MOGENRY BLA for severe-vision-loss retinitis pigmentosa, moving a one-time optogenetic treatment toward potential approval without requiring mutation-specific genetic targeting.
Sungrow and Sunotec commission 600MWh Bulgaria battery storage project
Read how Sungrow’s Bulgaria 600MWh battery storage project could reshape 300274 stock sentiment, Europe grid flexibility and BESS growth.